Estradiol Valerate/Dienogest

- ▴ Estradiol valerate/dienogest is an oral contraceptive for women that combines the natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic formulation. - ▴ Estradiol valerate/dienogest demonstrated contraceptive efficacy in a large (n=1377), non-comparative, multicentre study in women aged 18–50 years, with 13 pregnancies over 1797.5 women-years of exposure generating an unadjusted Pearl Index (PI) of 0.73 (upper limit of 95% CI 1.24) [primary endpoint]. Six of the pregnancies were attributed to method failure, resulting in an adjusted PI, based on 1786.5 women-years of exposure, of 0.34 (upper limit of 95% CI 0.73). - ▴ In a double-blind study in 798 women aged 18–50 years, estradiol valerate/dienogest and ethinylestradiol/levonorgestrel demonstrated an acceptable bleeding pattern and level of cycle control, according to several co-primary endpoints. - ▴ As reported in the UK manufacturer’s summary of product characteristics, the unadjusted PI for women aged 18–35 years or 18–50 years in a pooled analysis of clinical studies was 1.01 (upper limit of 95% CI 1.59) and 0.79 (upper limit of 95% CI 1.23). This pooled analysis of three studies excluded those pregnancies occurring within 14 days of the cessation of therapy. - ▴ Estradiol valerate/dienogest was generally well tolerated in this population, with the nature of adverse events generally similar across the studies and between estradiol valerate/dienogest and ethinylestradiol/levonorgestrel. Similar content being viewed by others

Moore C, Elger W, Graeser T, et al. Different alternatives for the substitution of ethinylestradiol in oral contraceptives. In: Kuhl H, Nikolov R, editors. Re-evaluation of contraceptive steroids. Bad Blankenburg: Harfe Verlag, 1998: 25–35 Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008 Sep; 78(3): 218–25 Rowlands S. New technologies in contraception. BJOG 2009 Jan; 116(2): 230–9 Wellington K, Perry CM. Estradiol valerate/dienogest. Drugs 2002; 62(3): 491–504; discussion 505-6 Loose DS, Stancel G.M. Estrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2005: 1541–71 Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995; 31(7): 517–36 Oetell M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 1995; 31(7): 499–516 Bayer plc. Qlaira summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/21700/SPC/Qlaira/ [Accessed 2009 Jun 3] Parke S, Junge W, Mellinger U, et al. Comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters [abstract no. O-193]. Hum Reprod 2008; 23 Suppl. 1: i78–9. Plus oral presentation from the 24th Annual Meeting of the European Society of Human Reproduction and Embryology; 2008 Jul 6–9; Barcelona Parke S, Nahum GG, Mellinger U, et al. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest [abstract]. Obstet Gynecol 2008 Apr; 111 (Suppl. 4): 12–3S. Plus poster presentation from the American College of Obstetricians and Gynecologists 56th Annual Clinical Meeting; 2008 May 3–7; New Orleans (LA) Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009 Jun; 14(3): 221–32 Ahrendt H-J, Makalová D, Parke S, et al. Bleeding patterns and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized, comparative trial of estradiol valerate/dienogest and ethinyl estradiol/ levonorgestrel. Contraception. Epub 2009 May 14 Nahum GG, Parke S, Wildt L, et al. Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest [abstract]. Obstet Gynecol 2008 Apr; 111 Suppl. 4: 15S. Plus poster presentation from the American College of Obstetricians and Gynecologists 56th Annual Clinical Meeting; 2008 May 3–7; New Orleans (LA) Nelson A, Sampson-Landers C, Parke S, et al. Efficacy of estradiol valerate/dienogest OC: results of 3 large studies in North America and Europe [abstract plus poster presentation]. The American College of Obstetricians and Gynecologists 57th Annual Clinical Meeting; 2009 May 2–6; Chicago (IL) Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993 Jun; 47(6): 583–90 Bayer Schering Pharma. Data on File. 2009 Bayer Schering Pharma. First estradiol-based oral contraceptive Qlaira® cleared for market launch in Europe [online]. Available from URL: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews[tt_news]=12755&cHash=22c735fdf3 [Accessed 2009 Apr 24] Bayer Schering Pharma. Bayer Schering Pharma paves the way to the next important oral contraceptive milestone [online]. Available from URL: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews[tt_news]=12170&cHash=c42fcdc686 [Accessed 2009 Apr 24] Bayer Schering Pharma. Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S. [online]. Available from URL: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&no_cache=1&tx_ttnews[tt_news]=13235 [Accessed 2009 Jul 9] Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Hoy, S.M., Scott, L.J. Estradiol Valerate/Dienogest. Drugs 69, 1635–1646 (2009). https://doi.org/10.2165/11202820-000000000-00000 Published: Issue date: DOI: https://doi.org/10.2165/11202820-000000000-00000